Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well combination chemotherapy with or without rituximab works
in treating participants with stage III-IV classic Hodgkin lymphoma. Monoclonal antibodies,
such as rituximab, may interfere with the ability of tumor cells to grow and spread. Drugs
used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and
dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab
with combination chemotherapy may work better in treating participants with classic Hodgkin
lymphoma.